Open AccessMALDI imaging mass spectrometry: bridging biology and chemistry in drug development
Author(s) -
Stephen Castellino,
M. Reid Groseclose,
David S. Wagner
Publication year - 2011
Publication title -
bioanalysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.566
H-Index - 58
eISSN - 1757-6199
pISSN - 1757-6180
DOI - 10.4155/bio.11.232
Subject(s) - drug development , mass spectrometry imaging , drug , drug metabolism , chemistry , tissue distribution , distribution (mathematics) , pharmacokinetics , mass spectrometry , computational biology , pharmacology , chromatography , medicine , biology , physiology , mathematical analysis , mathematics
Our understanding of drug tissue distribution impacts a number of areas in drug development, including: pharmacology, pharmacokinetics, safety, drug–drug interactions, transport and metabolism. Despite their extensive use, autoradiography and tissue homogenate LC–MS analysis have limitations in providing a comprehensive assessment of tissue distributions. In the case of autoradiography, it is the inability to distinguish between parent drug and drug metabolites. In LC–MS analysis of tissue homogenate, all tissue localization information is lost. The emerging technique of MALDI imaging mass spectrometry has the capability to distinguish between parent and metabolites while maintaining spatial distribution in tissues. In this article, we will review the MALDI imaging MS methodology as applied to drug development and provide examples highlighting the impact of this important technique in drug development.